The efficacy of S.aureus vaccines can be enhanced by adjuvanting S.aureus antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. A S.aureus antigen can also be adsorbed to the metal salt.